Related Experiment Video
Updated: May 24, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
1Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. MCL40@pitt.edu
Summary
Comparative effectiveness research for rheumatoid arthritis (RA) biologic disease-modifying anti-rheumatic drugs (DMARDs) is increasing. This data is crucial for optimizing RA treatment and guiding clinical decisions on biologic DMARDs.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a prevalent inflammatory condition causing joint destruction.
- Biologic disease-modifying anti-rheumatic drugs (DMARDs) have improved RA treatment but lack clear comparative efficacy data.
- Physicians and patients need better information on the comparative effectiveness of different biologic DMARDs for optimal RA management.
Purpose of the Study:
- To review the current landscape of comparative effectiveness research for biologic DMARDs in RA treatment.
- To highlight the importance of head-to-head trials and real-world evidence in guiding clinical decisions.
- To discuss the growing interest in comparative studies driven by governmental and organizational initiatives.
Main Methods:
- Review of published randomized trials directly comparing biologic DMARDs for RA.
- Analysis of studies estimating relative efficacy by comparing outcomes in patients with inadequate response to prior therapies (methotrexate or TNF antagonists).
- Inclusion of recent studies comparing biologic DMARDs with optimal oral DMARD combinations.
Main Results:
- Prior to 2008, direct comparative trials were absent; several have been published since.
- Studies suggest rituximab may offer higher response rates than other TNF antagonists in patients who failed prior TNF antagonist therapy.
- The ATTEST trial indicated comparable response rates between abatacept and infliximab for methotrexate-refractory RA patients.
Conclusions:
- A growing body of comparative effectiveness research exists for biologic DMARDs in RA, though more data is needed.
- Comparative data is essential for optimizing RA treatment strategies and managing costs/side effects.
- Increased pharmaceutical interest and governmental support suggest a future with more robust comparative data for biologic DMARDs in RA.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...